trending Market Intelligence /marketintelligence/en/news-insights/trending/5h1F2phQjZRnhwSJFznW2w2 content esgSubNav
In This List

Alliance Pharma completes acquisition of TyraTech's head lice treatment

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Alliance Pharma completes acquisition of TyraTech's head lice treatment

Alliance Pharma plc completed its acquisition of the worldwide rights to TyraTech, Inc.'s Vamousse.

TyraTech's shareholders approved the deal on Dec. 27.

Vamousse assets comprise consumer healthcare products for preventing and treating human head lice.